CorpusHuman Anatomy

Proteasome

Proteasoma

Also known as: 26S proteasome, ubiquitin–proteasome system, ubiquitin

A barrel-shaped, ATP-dependent protease complex (26S) in the cytosol and nucleus that destroys proteins tagged with chains of ubiquitin.

The Eukaryotic Cell

Overview

Sedimentation26S = 20S core + 19S cap(s)
Degradation signal≥4 Lys48-linked ubiquitins

Selective destruction of individual proteins is carried out by the ubiquitin–proteasome system. Ubiquitin, a 76-amino-acid protein, is attached to lysine residues of target proteins by an enzyme cascade: E1 (activating, uses ATP), E2 (conjugating) and E3 (ligase, of which there are hundreds, conferring substrate specificity). A chain of ≥4 ubiquitins linked through lysine-48 marks the protein for degradation.

The 26S proteasome (≈2.5 MDa) consists of a 20S core particle — a hollow cylinder of four stacked seven-membered rings (α7β7β7α7) whose inner β-subunits have caspase-like, trypsin-like and chymotrypsin-like activity — capped at one or both ends by a 19S regulatory particle. The cap recognises polyubiquitin, removes and recycles the ubiquitin, and uses ATPases to unfold the substrate and thread it into the core, where it is cut into short peptides (≈3–25 amino acids).

Substrates include misfolded proteins (including those retro-translocated from the ER by ERAD) and short-lived regulators such as cyclins, securin, p53 (via the E3 MDM2), IκB (allowing NF-κB activation) and β-catenin. Peptides produced by immunoproteasomes (induced by interferon-γ) are loaded onto MHC class I molecules for presentation to cytotoxic T cells.

Location

Cytosol and nucleus (non-membranous).

Parts & subdivisions

  1. 20S core particle
    Proteolytic chamber; α rings form gates, β rings carry three catalytic activities.
  2. 19S regulatory particle (cap)
    Binds ubiquitinated substrates, deubiquitinates them and unfolds them using six AAA-ATPases.

Function

  • Degradation of misfolded and damaged proteins (protein quality control).
  • Timed destruction of regulatory proteins (cyclins, securin, p53, IκB) — controls the cell cycle, signalling and transcription.
  • Generation of antigenic peptides for MHC class I presentation.

Clinical significance

Proteasome inhibitors

Bortezomib, carfilzomib and ixazomib treat multiple myeloma and mantle-cell lymphoma: antibody-producing plasma cells are especially sensitive to accumulation of unfolded proteins. Adverse effects include peripheral neuropathy.

Ubiquitin-ligase disorders

Parkin (E3 ligase) mutations cause autosomal recessive juvenile Parkinson disease; loss of maternal UBE3A (E3 ligase) causes Angelman syndrome; HPV E6 hijacks the E3 ligase E6AP to degrade p53.

Test yourself

Bortezomib, used in multiple myeloma, inhibits:
  1. The 26S proteasome
  2. Lysosomal cathepsins
  3. Topoisomerase I
  4. Microtubule polymerisation

Answer: The 26S proteasome

Blocking the proteasome causes misfolded immunoglobulin and pro-apoptotic proteins to accumulate, triggering the unfolded-protein response and apoptosis in antibody-producing plasma cells.

More cells & tissues questions

Compiled from standard anatomy and physiology references — see the Cells & Tissues sources. For education only; not medical advice.